The US FDA has approved Doxorubicin-HCI Liposomal Injection from Israel’s Ayana for the treatment of ovarian cancer, multiple myeloma, and Kaposi’s Sarcoma. The novel chemotherapy was developed by Hebrew University professor Yechezkel Barenholz (see here and here). https://www.jpost.com/health-and-wellness/generic-cancer-killing-israeli-drug-approved-for-marketing-by-fda-682430

was developed 40 years ago. Liposome’s co-inventor, Prof. Yechezkel Barenholz was honoured on his 70th birthday. He hosted a Liposome conference to 300 international specialists. http://www.jpost.com/Sci-Tech/Article.aspx?id=226558